GlassScriptPhysician profile
Michael A Giglio
NPI 1770780850
$13,958.66
in general payments reported to CMS, 2019-2025
80 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,721 · 2020: $707 · 2021: $2,230 · 2022: $3,169 · 2023: $1,933 · 2024: $1,944 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,131.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,499.54 | 2019-2025 | |
| Biogen, INC. | $1,217.28 | 2019-2024 | Vumerity, Tysabri, Tysabri |
| Amgen INC. | $1,134.80 | 2019-2025 | Uplizna, Aimovig |
| Collegium Pharmaceutical, INC. | $1,005.29 | 2021-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $841.89 | 2020-2023 | Infinity |
| Pfizer INC. | $831.48 | 2019-2025 | |
| Boston Scientific Corporation | $512.05 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $430.80 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $329.43 | 2021-2025 | Hetlioz, Ponvory |
| Amneal Pharmaceuticals LLC | $317.41 | 2020-2025 | Crexont, Lyvispah |
| Teva Pharmaceuticals USA, INC. | $305.77 | 2019-2025 | Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.46 | 2019-2025 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $278.82 | 2022 | |
| Ucb, INC. | $270.20 | 2019-2025 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $266.48 | 2019-2025 |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Giglio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.